Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental cancer drug tested in humans for first time

NCT ID NCT06130722

Summary

This first-in-human study tested the safety of a new cancer drug called FL115 in patients with advanced solid tumors that have stopped responding to standard treatments. The trial enrolled 18 adults to receive increasing doses of FL115 given weekly through an IV, with careful monitoring for side effects. The main goal was to determine the highest safe dose and understand how the drug behaves in the body before testing its effectiveness against cancer in future studies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Gabriel Cancer Center

    Canton, Ohio, 44718, United States

  • HOAG Memorial Hospital Presbyterian

    Newport Beach, California, 92663, United States

  • Moores Cancer Center at UCSD Health

    San Diego, California, 92037, United States

Conditions

Explore the condition pages connected to this study.